Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients - Hackaday

What the report says

Hackaday reported on a recent study by Olivia Kim-McManus and colleagues that tested individualized antisense therapy in two boys with SCN2A mutations, a rare genetic condition linked to severe epilepsy and developmental disorders. The gene is important in the central nervous system because it helps regulate NaV1.2 sodium channels, which are involved in initiating action potentials. According to the report, SCN2A mutations affect roughly 1 in 80,000 people and are usually not inherited.

The article explains that antisense therapy targets messenger RNA, the intermediate step between DNA and protein production, rather than directly editing DNA or only treating symptoms. In these cases, researchers designed antisense oligonucleotides, or ASOs, to target the faulty allele while avoiding the healthy copy of the gene. That allele-specific approach was intended to reduce production of the abnormal sodium channels associated with gain-of-function mutations.

Hackaday said the two patients were 9- and 14-year-old boys with severe developmental and epileptic encephalopathies who continued to have daily seizures despite sodium-channel blockers and other medications. The 9-year-old received 12 ASO doses over 24 months and had fewer seizures, with phenytoin stopped. The 14-year-old received eight doses over 16 months, with average seizures reportedly falling from two per day to none.

The report also noted observed improvements beyond seizure control, including language, motor skills and behavior, with the older boy later able to walk without assistance. Hackaday framed the findings as early evidence that allele-specific ASOs could offer a more targeted option than standard anti-seizure medication, while noting that permanent gene-level approaches, including CRISPR-based research in mice, remain an area of investigation.